Hepatitis B Vaccine Trial (Phase Ia)
Recruitment for participants in the Phase 1a trial has already been completed.
Participants living with hepatitis B are currently invited to take part in the Phase 1b/2a follow-up trial. If you are interested in taking part in the trial, you can register here (TherVacB website).
Over three percent of the world's population (approx. 260 million people) are chronically infected with the hepatitis B virus (HBV). Worldwide, 880,000 people die every year as a result of HBV infection (including liver cirrhosis and liver cancer). Prophylactic vaccines are available to prevent HBV infection. There is currently no curative treatment for chronically infected people.
The Institute of Infectious Diseases and Tropical Medicine at the LMU University Hospital Munich is conducting a Phase I vaccine trial with the therapeutic vaccine candidate TherVacB against hepatitis B in collaboration with the Institute for Infection Research and Vaccine Development Hamburg (Prof. Addo) and Helmholtz Munich (Prof. Protzer). The trial contributes to the research of a novel therapeutic approach to cure chronic hepatitis B in the TherVacB project.
TherVacB is a publicly funded academic research project. Further information on the project can be found at www.thervacb.eu and www.dzif.de.
Recruitment for participants in the Phase 1a trial has already been completed.
Participants living with hepatitis B are currently invited to take part in the Phase 1b/2a follow-up trial. If you are interested in taking part in the trial, you can register here (TherVacB website).
Phase 1a clinical trial (enrollment completed)
Phase 1a clinical trial, we were looking for healthy women and men between the ages of 18 and 65. The study included a preliminary examination and 12 outpatient visits over a period of approx. 9 months.
General requirements for participation in the phase 1a clinical trial
- 18-65 years
- in good health
for women: not pregnant or breastfeeding
not vaccinated against Mpox (formerly monkeypox) or hepatitis B
no hepatitis B infection in the past
- no regular intake of medication
- BMI (Body Mass Index): 18.5-32.0 kg/m²
- Body weight: at least 50 kg
In addition to comprehensive information about the trial and in-depth medical care, you will receive an expense allowance of € 1,800.00 if you participate fully.
Contact
Monday - Thursday:
9a.m. to 2.30 p.m.
Tel: 089 4400-59850
E-Mail:
impfstudien-tropeninstitut@
med.uni-muenchen.de
Please state the keyword "Hepatitis B" in your e-mail.
Cooperation partner
